MEND Micrus Endovascular (MM)

Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/mend) is investigating potential claims against the board of directors of Micrus Endovascular Corporation ("Micrus" or the "Company") (NASDAQ: MEND) concerning possible breaches of fiduciary duty and other violations of law related to the Company's entry into an agreement to be acquired by Johnson & Johnson in a transaction valued at approximately $480 million.

Our investigation concerns possible breaches of fiduciary duty and other violations of law related to approval of the transaction by Company’s board of directors; in particular, whether the Company undertook a fair process to obtain fair consideration for all shareholders of Micrus. For more information regarding our investigation, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at rmaniskas@rmclasslaw.com or visit: www.rmclasslaw.com/cases/mend.

Under the terms of the agreement, Micrus stockholders will receive at closing $23.40 for each outstanding Micrus share.

If you own shares of Micrus and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/mend. You may also email Mr. Maniskas at rmaniskas@rmclasslaw.com. For more information about class action cases in general, please visit our website: www.rmclasslaw.com.

Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan and Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.

Micrus Endovascular (MM) (NASDAQ:MEND)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024

Micrus Endovascular (MM) (NASDAQ:MEND)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024